Is it time to move away from short-acting beta-agonists in asthma management?

Abstract
Frequent SABA use is associated with adverse asthma outcomes and evidence suggests replacing SABA with fast-acting LABA/ICS as reliever therapy reduces asthma exacerbation risk. We believe the time has come to move away from SABAs in asthma management. http://ow.ly/87UJ30nVGNc

This publication has 26 references indexed in Scilit: